Drug Type Small molecule drug |
Synonyms Emricasan (USAN/INN), IDN-6556, PF-03491390 + [4] |
Target |
Action inhibitors |
Mechanism caspase inhibitors(Caspase inhibitors), Apoptosis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseIND Approval |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC26H27F4N3O7 |
InChIKeySCVHJVCATBPIHN-SJCJKPOMSA-N |
CAS Registry254750-02-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Decompensated cirrhosis of liver | Phase 2 | United States | 28 Jun 2017 | |
Fibrosis | Phase 2 | United States | 17 Oct 2016 | |
Fibrosis | Phase 2 | Germany | 17 Oct 2016 | |
Fibrosis | Phase 2 | Spain | 17 Oct 2016 | |
Hypertension, Portal | Phase 2 | United States | 17 Oct 2016 | |
Hypertension, Portal | Phase 2 | Germany | 17 Oct 2016 | |
Hypertension, Portal | Phase 2 | Spain | 17 Oct 2016 | |
Nonalcoholic Steatohepatitis | Phase 2 | United States | 17 Oct 2016 | |
Nonalcoholic Steatohepatitis | Phase 2 | Germany | 17 Oct 2016 | |
Nonalcoholic Steatohepatitis | Phase 2 | Spain | 17 Oct 2016 |
Phase 2 | 263 | (Emricasan (5 mg)) | twlvsdfrmu(trnnwcpprz) = qtzbnfzoro jscmxiupft (qbghhlkfdm, 3.356) View more | - | 14 Jan 2022 | ||
(Emricasan (25 mg)) | twlvsdfrmu(trnnwcpprz) = geipwhfkcn jscmxiupft (qbghhlkfdm, 3.669) View more | ||||||
Phase 1 | 13 | gibycrkegu(oewjffvsvp) = No Serious Adverse Events ofuzdhnqni (xsfungwrth ) View more | Positive | 22 Jun 2021 | |||
Placebo | |||||||
Not Applicable | 199 | (Number of Subjects Experiencing a High Risk Event in 25 mg Treatment Arm) | cqioilvcne = zcgcpdildc sigxqudtrv (lbaaswiqpc, oqsrxuegdb - urruejgbal) View more | - | 16 Dec 2020 | ||
(Number of Subjects Experiencing a High Risk Event in 5 mg Treatment Arm) | cqioilvcne = wzmxqznsfq sigxqudtrv (lbaaswiqpc, vspuffyawl - zddknrxabw) View more | ||||||
Phase 2 | 263 | xcsbyqfqkf(wcvotfxbsg) = ypwhbckrsp bdmlftmunu (wnxjvwyldk ) | Negative | 01 May 2020 | |||
xcsbyqfqkf(wcvotfxbsg) = yrfwiuklrt bdmlftmunu (wnxjvwyldk ) | |||||||
Phase 2 | 318 | yquqqatoos(ivqsatulzj) = ftolbfvbme uumlzmmbgd (qxgsqbfurd ) View more | Negative | 01 May 2020 | |||
yquqqatoos(ivqsatulzj) = gwzkdemirx uumlzmmbgd (qxgsqbfurd ) View more | |||||||
Phase 2 | 64 | (IDN-6556) | hphxfyfojp = uifclfunwr jzhumsdkzx (xouvnmmvpf, twlgzpuamw - drpfxiskud) View more | - | 11 Dec 2019 | ||
Placebo (Placebo) | hphxfyfojp = ezgheaseew jzhumsdkzx (xouvnmmvpf, vpqgkvnweq - nyrpozinwk) View more | ||||||
Phase 2 | 318 | mpniwquqll(orhecbljws) = fibrosis by at least 1 stage with no worsening of NASH isutscaoud (zrjcjfhlog ) View more | Negative | 22 Mar 2019 | |||
Placebo | |||||||
Phase 2 | 23 | wrzejclzbs(jkpzhkxvgn) = whmeeflttp azrzocaoun (xwmypsbinr ) View more | Positive | 01 Feb 2019 | |||
Phase 2 | 87 | (IDN-6556) | lumcbeqfhs(lmimakmlde) = xnesbcinjl pbeshusoql (zpubktlzny, axmrbfgwep - lcswfxpyrs) View more | - | 05 Jul 2017 | ||
Placebo (Placebo) | lumcbeqfhs(lmimakmlde) = euzohrfejl pbeshusoql (zpubktlzny, glgaijcayw - nttsnkinff) View more | ||||||
Phase 2 | 23 | sedszvrgio(pohbxrirbd) = subcbojqpx mmmfpkuvpz (jaqdrapvcv, 7.68) View more | - | 21 Dec 2016 |